The Global Antiparasitic Drugs Market, by Drug Class (Anthelmintics (Benzimidazoles, Pyrantel, Niclosamide, Praziquantel, and Others), Antiprotozoals (Antimalarial Drugs-Aminoquinolines, Quinoline-methanol (4-quinolinemethanols), Cinchona Alkaloids, Biguanides, Sulfonamides and sulfones, Others), and Other Antiprotozoal Agents), and Others (Pediculocides & miticulocides) (Lindane, Malathion, Pyrethrins, and Others), by Route of Administration (Oral, Injectable, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$  7,227.9 million in 2019 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The increasing launches of antiparasitic drugs is expected to propel growth of the global antiparasitic drugs market during the forecast period. For instance, in August 2019, Teva Pharmaceuticals launched an AB-rated generic version of Galderma’s Soolantra (ivermectin) cream indicated for the treatment of inflammatory lesions of rosacea. Moreover, in January 2018, Perrigo Company plc. received tentative U.S. Food and Drug Administration approval to launch generic version of the Soolantra (ivermectin) cream.

Browse 42 Market Data Tables and 40 Figures spread through 182 Pages and in-depth TOC on 'Global Antiparasitic Drugs Market, (Anthelmintics (Benzimidazoles, Pyrantel, Niclosamide, Praziquantel, and Others), Antiprotozoals (Antimalarial Drugs-Aminoquinolines, Quinoline-methanol (4-quinolinemethanols), Cinchona Alkaloids, Biguanides, Sulfonamides and sulfones, Others), and Other Antiprotozoal Agents), and Others (Pediculocides & miticulocides) (Lindane, Malathion, Pyrethrins, and Others), by Route of Administration (Oral, Injectable, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027'

To know the latest trends and insights related to Antiparasitic Drugs Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/antiparasitic-drugs-market-3782

Initiatives taken by government and non-profit organizations to create awareness related to the parasitic diseases among the population and providing proper treatment is contributing to the market growth. Moreover, these organization are focusing on establishing new research and development centers in high risk tropical and subtropical regions. For instance, in June 2018, the University of California San Diego launched a new Center for Anti-Parasitic Drug Discovery and Development at San Diego which includes 15 research and clinical facilities.

Furthermore, the increasing prevalence of parasitic infections such as Chagas Disease is expected to drive the market growth. According to the World Health Organization (WHO) estimation, in March 2020, around 6-7 million people across the globe are expected to be diagnosed with Chagas Disease, a parasitic infection caused due the Trypansosoma cruzi parasite. The WHO also stated that majority of the affected population is from the Latin America region. The Chagas Disease can be well treated with benznidazole and nifurtimox. Thus, the increasing prevalence of the Chagas disease is expected to drive demand for these drugs in the region.

Key Takeaways of the Global Antiparasitic Drugs Market:

  • The global antiparasitic drugs market is expected to exhibit a CAGR of 5.2% during the forecast period (2020–2027) owing to initiatives taken by various research organizations to develop novel drugs for treating parasitic diseases. For instance, on April 23, 2019 Lupin Research Inc. initiated phase 3 study to evaluate the effectiveness, and safety of a single, oral dose of Solosec containing 2 grams of secnidazole in female patients with trichomoniasis. The study is estimated to be completed in 2020.
  • Among drug class, antiprotozoals is expected to hold significant market share in antiparasitic drugs market owing to the growing demand for antimalarial drugs in key regions such as India and other South-east Asian countries, as well as high prevalence of malaria in these countries is expected to drive growth of antiparasitic drugs market. For instance, according to the WHO, in 2017, around 3 million cases of malaria were diagnosed in India. Moreover, the WHO stated that in 2019, India accounted for 21% of the total deaths in South-east Asia region.
  • Major players operating in the global antiparasitic drugs market are Ipca Laboratories Ltd., Zydus Cadila, Merck KGaA, Pfizer, GlaxoSmithKline Plc., Cipla Ltd, Ranbaxy Laboratories, Novartis AG, Alvizia Health Care, Bayer AG, Roche Inc., Arbor Pharmaceuticals Inc., Sanofi, AstraZeneca plc. and Alkem Laboratories Limited.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner